Matching Your Gift Dollar for Dollar
The Salk Institute is recruiting a new Assistant Professor, Dr. Christina Towers, to the Salk Cancer Center. In honor of the Conquering Cancer Initiative, the BioMed Realty Management Team is issuing a challenge match – they will match, dollar for dollar, up to $1M, to support Towers’ recruitment and to support her research and that of the Salk Cancer Center. BioMed’s president and CEO, Tim Schoen, is a Salk trustee and chairman of the Institute’s Conquering Cancer Initiative Advisory Committee.
A definition of translational research is integrating fundamental scientific discoveries and patient-oriented research with a long-term aim of improving human health.
The Salk Cancer Center, an NCI-Designated Basic Laboratory Cancer Center, strives to move research discoveries from the basic science laboratory into preclinical studies and advanced stages of development to help in the prevention, diagnosis, and treatment of human disease. Translating early discoveries into clinical trials is complex and requires significant funding and a longer timeframe to complete. For most philanthropic donors, private foundations, and public funding streams, this process is not a priority due to cost and the time to realize a benefit. The result is that many discoveries that can improve human health cannot receive the investments needed to see a beneficial outcome.
Advancing Salk science is our goal, and creating an opportunity to maximize the benefit to human health from the discoveries made in Salk labs is fundamental to our mission. Scientists from the Salk Cancer Center collaborate daily with clinicians at UC San Diego, City of Hope, and other cancer centers worldwide. These collaborations allow Salk scientists to access patient samples and data for research purposes, design and run clinical trials to test the efficacy of potential treatments and advance successful discoveries into products or tools to improve patient care and health outcomes.
The Cancer Center Translational Fund
By creating the new Translational Fund through philanthropic support, the Salk Institute will be able to bolster a select number of outstanding projects and de-risk early discoveries towards commercial readiness and into valuable assets that will be partnered with industry. Through translational development, we expect to reach milestones that demonstrate the value or reduce the risk of Salk innovations to potential industry partners or investors that will help be the channels to advance Salk innovations into the marketplace. The Translation Fund will build on Salk’s continued success of bringing discoveries to benefit the public good ensuring and ensure we capture greater value for the Institute and our scientific teams with the added benefit of building a sustainable program of funding for future innovations.
Philanthropic support for the Translational Fund is an essential part of our mission to change the world for the better. By investing in the long-term scientific research conducted through the Cancer Center at the Salk Institute, you can help shape the future of human health. If you are interested in learning more, please contact Sandy Liarakos at email@example.com.
Thank you for attending the recent Salk Institute program: The Power of Science: Conquering Pancreatic Cancer. Below is the link to the program recording and also two additional videos and the research being done on colon cancer.
If you would like to make a gift to the Salk Pancreatic Cancer Program, please visit this online giving link.
November 16, 2020
Colon Cancer Research at Salk – Ronald Evans, PhD – http://www.salk.edu/pr2019-02-21
Sandy Liarakos, CFRE
Senior Director of External Relations
Tim Schoen, Chair
Susan Pidgeon Mandel
Reuben Shaw, PhD
Cancer Center Director
Senior Director, External Relations
Did you know that Salk Cancer Center has been leading the way in conquering cancer since 1970? Find Out How »
Introduction by Cancer Center Director, Reuben Shaw
Panel discussion with Ronald Evans, Tony Hunter and Dannielle Engle
April 20, 2018 – Highlights from Keynote Presentation by Joseph R. Biden, Jr.